203 related articles for article (PubMed ID: 33782314)
1. Discordant Uptake Between Diagnostic 68Ga-HA-DOTATATE PET/CT and Posttherapy 177Lu-HA-DOTATATE SPECT/CT in Patients With Neuroendocrine Tumors.
Huizing DMV; Aalbersberg EA; van der Hiel B; Stokkel MPM; Versleijen MWJ
Clin Nucl Med; 2021 Sep; 46(9):e475-e477. PubMed ID: 33782314
[TBL] [Abstract][Full Text] [Related]
2. 177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers.
Peterson AB; Wang C; Wong KK; Frey KA; Muzik O; Schipper MJ; Dewaraja YK
Clin Nucl Med; 2023 May; 48(5):393-399. PubMed ID: 37010563
[TBL] [Abstract][Full Text] [Related]
3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
4. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
5. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor.
Parghane RV; Basu S
Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741
[TBL] [Abstract][Full Text] [Related]
6. The effect of long-acting somatostatin analogues on the uptake of [
Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536
[TBL] [Abstract][Full Text] [Related]
7. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
[TBL] [Abstract][Full Text] [Related]
8. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
Zahed H; Beauregard JM; Abikhzer G; Rush C; Probst S
Clin Nucl Med; 2023 Jan; 48(1):e12-e15. PubMed ID: 36240803
[TBL] [Abstract][Full Text] [Related]
9. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
[TBL] [Abstract][Full Text] [Related]
10. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
11. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
16. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
17. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
[TBL] [Abstract][Full Text] [Related]
18. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
